Kaka J S, Al-Khamis K I, Tanira M O
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Eur J Drug Metab Pharmacokinet. 1988 Jul-Sep;13(3):149-53. doi: 10.1007/BF03189933.
Disposition of bupropion after oral administration was investigated in carbon tetrachloride (CCl4) and gentamicin treated rats. Bupropion exhibits extensive first-pass effect and is mainly cleared by hepatic route. In rats with hepatic damage, maximum plasma concentration (Cmax) was approximately 3 times higher and area under the plasma concentration-time curve up to 6 h (AUC 0-6) and AUC 0-infinity increased on an average 4 and 5 times respectively compared to the control. The half-life was doubled with hepatic dysfunction. These findings suggest that hepatic impairment in rats causes a decrease in first pass effect as well as an increase in the half-life of the drug. Rats with renal impairment, exhibited a significant increase in Cmax, AUC 0-6 and AUC 0-infinity of bupropion approximately 3-fold as compared to the control, no change in half life of the drug was observed. This indicates that rats with renal impairment show less efficient first-pass effect which may lead to increase in systemic bioavailability. The time to peak observed in all treated animals was not significantly different from the control. The percentage of bound bupropion did not differ either in CCl4 or gentamicin treated plasma as compared to the control.
在四氯化碳(CCl4)和庆大霉素处理的大鼠中研究了口服安非他酮后的处置情况。安非他酮具有广泛的首过效应,主要通过肝脏途径清除。在肝损伤大鼠中,与对照组相比,最大血浆浓度(Cmax)大约高3倍,血浆浓度-时间曲线下面积至6小时(AUC 0-6)和AUC 0-无穷大平均分别增加4倍和5倍。肝功能不全时半衰期加倍。这些发现表明,大鼠肝损伤会导致首过效应降低以及药物半衰期延长。与对照组相比,肾功能受损的大鼠安非他酮的Cmax、AUC 0-6和AUC 0-无穷大显著增加约3倍,未观察到药物半衰期的变化。这表明肾功能受损的大鼠首过效应较低,这可能导致全身生物利用度增加。在所有处理的动物中观察到的达峰时间与对照组无显著差异。与对照组相比,CCl4或庆大霉素处理的血浆中结合安非他酮的百分比也没有差异。